Impressive lipid changes following hypolipidaemic drug administration can unveil subclinical hyperthyroidism

Diabetes Obes Metab. 2001 Apr;3(2):97-8. doi: 10.1046/j.1463-1326.2001.00133.x.

Abstract

It is well known that thyroid hormones modulate lipoprotein metabolism. Thus, the presence of clinical or subclinical hyperthyroidism may influence lipid parameters of dyslipidaemic patients and the efficacy of hypolipidaemic therapy. Here we present a patient with mixed hyperlipidaemia whose impressive improvement of his lipid profile following ciprofibrate administration pointed towards the diagnosis of asymptomatic underlying subclinical hyperthyroidism.

Publication types

  • Case Reports

MeSH terms

  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Clofibric Acid / analogs & derivatives
  • Clofibric Acid / therapeutic use
  • Fibric Acids
  • Humans
  • Hyperlipidemias / complications
  • Hyperlipidemias / drug therapy*
  • Hyperthyroidism / complications
  • Hyperthyroidism / diagnosis*
  • Hypolipidemic Agents / therapeutic use*
  • Lipids / blood*
  • Male
  • Middle Aged
  • Thyrotropin / blood
  • Thyrotropin-Releasing Hormone
  • Thyroxine / blood
  • Triglycerides / blood
  • Triiodothyronine / blood

Substances

  • Cholesterol, HDL
  • Cholesterol, LDL
  • Fibric Acids
  • Hypolipidemic Agents
  • Lipids
  • Triglycerides
  • Triiodothyronine
  • Clofibric Acid
  • Thyrotropin-Releasing Hormone
  • Thyrotropin
  • ciprofibrate
  • Thyroxine